2019 ACR/ARP Annual Meeting*

November 8-13, 2019; Atlanta, Georgia
Review the latest RA management data with Capsule Summaries and expert-authored commentaries covering key studies from ACR 2019.
Stanley B. Cohen, MD
Jonathan Kay, MD

ClinicalThought

MACE and VTE data were presented for all approved and phase III JAK inhibitors.

Stanley B. Cohen, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 5, 2019 Expired: December 4, 2020

Here’s how new strategies like ultralow-dose rituximab, a novel small molecule IRAK-4 inhibitor, and vagus nerve stimulation may or may not change clinical practice.

Jonathan Kay, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: January 9, 2020 Expired: January 8, 2021
Provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
Gilead Sciences
Mallinckrodt Pharmaceuticals

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue